Please use this identifier to cite or link to this item: https://ir.swu.ac.th/jspui/handle/123456789/27157
ชื่อเรื่อง: Efficacy, Safety, and Patient-Reported Outcomes of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Thailand: A Multicenter Prospective Study
ผู้แต่ง: Charonpongsuntorn C.
Tanasanvimon S.
Korphaisarn K.
Payapwattanawong S.
Siripoon T.
Pakvisal N.
Juengsamarn J.
Phaibulvatanapong E.
Chindaprasirt J.
Prasongsook N.
Udomdamrongkul K.
Ngamphaiboon N.
Sirachainan E.
วันที่เผยแพร่: 2022
สำนักพิมพ์: NLM (Medline)
บทคัดย่อ: PURPOSE: Atezolizumab plus bevacizumab treatment is a first-line therapy for unresectable hepatocellular carcinoma (HCC) worldwide. The efficacy, safety, and patient-reported outcomes (PROs) of HCC in Thailand have not yet been reported. This study aimed to evaluate the efficacy, safety, and PROs of atezolizumab plus bevacizumab. MATERIALS AND METHODS: From September 2020 to August 2021, 30 patients with unresectable HCC who met the inclusion criteria of atezolizumab plus bevacizumab as first-line treatment were enrolled. Analysis was assessed for progression-free survival, overall survival, adverse events (AEs), and quality of life (QoL). RESULTS: The median progression-free survival and overall survival periods were 6.7 and 10.2 months, respectively. The disease control rate was 63.3%. The frequent AEs were proteinuria, hypertension, and hepatitis. Serious AEs included gastrointestinal bleeding, but none of the patients died from serious AEs. The discontinuation rate was 23.3%, and the median number of treatment cycles was 10.5 cycles. In total, 23.3% of the patients continued treatment after 1 year of therapy. The global health status/QoL and physical function scores showed less deterioration at baseline than at 3 and 6 months (median scores = 76.7, 71.6, and 64.1 in QoL and 84.7, 79.6, and 79.0 in physical function, respectively). The HCC18 symptom score index data showed a slow progression of symptom scores from baseline to 3 and 6 months (12.7, 19.6, and 22.3, respectively). CONCLUSION: This study demonstrates that atezolizumab plus bevacizumab is effective and has a safety profile comparable with that of previous studies as first-line therapy for unresectable HCC in a real-world setting and in Thai populations. Data on PROs also demonstrate benefits in terms of patients' QoL and symptoms.
URI: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85143185862&doi=10.1200%2fGO.22.00205&partnerID=40&md5=722650828e41232eba02a2044f73045f
https://ir.swu.ac.th/jspui/handle/123456789/27157
ISSN: 26878941
Appears in Collections:Scopus 2022

Files in This Item:
There are no files associated with this item.


Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.